ATE152350T1 - Pharmazeutische zusammensetzungen die 5- difluormethoxy-2-(3,4-dimethoxy-2- pyridyl)methylsulfinyl>-1h-benzimidazol und ein anti-heliobactermittel enthalten zur behandlung von magen-darm krankheiten - Google Patents

Pharmazeutische zusammensetzungen die 5- difluormethoxy-2-(3,4-dimethoxy-2- pyridyl)methylsulfinyl>-1h-benzimidazol und ein anti-heliobactermittel enthalten zur behandlung von magen-darm krankheiten

Info

Publication number
ATE152350T1
ATE152350T1 AT91915307T AT91915307T ATE152350T1 AT E152350 T1 ATE152350 T1 AT E152350T1 AT 91915307 T AT91915307 T AT 91915307T AT 91915307 T AT91915307 T AT 91915307T AT E152350 T1 ATE152350 T1 AT E152350T1
Authority
AT
Austria
Prior art keywords
pharmaceutical compositions
benzimidazole
heliobacter
methylsulfinyl
difluoromethoxy
Prior art date
Application number
AT91915307T
Other languages
English (en)
Inventor
Michael E Parsons
Original Assignee
Byk Gulden Lomberg Chem Fab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10681166&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE152350(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Byk Gulden Lomberg Chem Fab filed Critical Byk Gulden Lomberg Chem Fab
Application granted granted Critical
Publication of ATE152350T1 publication Critical patent/ATE152350T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/245—Bismuth; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
AT91915307T 1990-08-24 1991-08-23 Pharmazeutische zusammensetzungen die 5- difluormethoxy-2-(3,4-dimethoxy-2- pyridyl)methylsulfinyl>-1h-benzimidazol und ein anti-heliobactermittel enthalten zur behandlung von magen-darm krankheiten ATE152350T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB909018603A GB9018603D0 (en) 1990-08-24 1990-08-24 Compositions

Publications (1)

Publication Number Publication Date
ATE152350T1 true ATE152350T1 (de) 1997-05-15

Family

ID=10681166

Family Applications (1)

Application Number Title Priority Date Filing Date
AT91915307T ATE152350T1 (de) 1990-08-24 1991-08-23 Pharmazeutische zusammensetzungen die 5- difluormethoxy-2-(3,4-dimethoxy-2- pyridyl)methylsulfinyl>-1h-benzimidazol und ein anti-heliobactermittel enthalten zur behandlung von magen-darm krankheiten

Country Status (13)

Country Link
EP (1) EP0544760B1 (de)
JP (1) JPH06503806A (de)
KR (1) KR930701166A (de)
AT (1) ATE152350T1 (de)
AU (1) AU658831B2 (de)
CA (1) CA2089748C (de)
CY (1) CY2167B1 (de)
DE (1) DE69125940T2 (de)
DK (1) DK0544760T3 (de)
ES (1) ES2103825T3 (de)
GB (1) GB9018603D0 (de)
GR (1) GR3024058T3 (de)
WO (1) WO1992003135A1 (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW276996B (de) * 1992-04-24 1996-06-01 Astra Ab
WO1994013290A1 (de) * 1992-12-10 1994-06-23 Byk Gulden Lomberg Chemische Fabrik Gmbh Verwendung von alkylthiopyridinen zur bekämpfung von heliobacter-bakterien
WO1994027606A1 (en) * 1993-05-28 1994-12-08 Unisearch Limited Method of treating helicobacter pylori infection
EP0995447A1 (de) * 1993-09-09 2000-04-26 Takeda Chemical Industries, Ltd. Formulierung enthaltend einen Antibakteriellen und einen Antiulcus Wirkstoff
TW420610B (en) * 1994-04-07 2001-02-01 Pfizer A pharmaceutical composition for treating a H. pylori infection or gastric or duodenal ulcers
JP3042890B2 (ja) * 1994-11-21 2000-05-22 ファイザー製薬株式会社 フタリド化合物及びその製法
SE9500422D0 (sv) * 1995-02-06 1995-02-06 Astra Ab New oral pharmaceutical dosage forms
US5945124A (en) * 1995-07-05 1999-08-31 Byk Gulden Chemische Fabrik Gmbh Oral pharmaceutical composition with delayed release of active ingredient for pantoprazole
US6303644B1 (en) * 1997-07-25 2001-10-16 Byk Gulden Lomberg Chemische Fabrik Gmbh Proton pump inhibitor in therapeutic combination with antibacterial substances
WO2005074898A2 (en) * 2004-01-28 2005-08-18 Altana Pharma Ag Composition comprising (s) pantoprazole and an antibiotic for treating helicobacter pylori
EP2601947A1 (de) 2011-12-05 2013-06-12 Abo Bakr Mohammed Ali Al-Mehdar Kombinationspräparat mit fester Dosierung zur Behandlung von Erkrankungen einhergehend mit Helicobacter pylori

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL85472A (en) * 1987-03-09 1991-06-30 Procter & Gamble Pharmaceutical compositions for treating gastrointestinal disorders
JP2733849B2 (ja) * 1987-10-12 1998-03-30 ボロディー，ソーマス・ユリウス 胃腸障害治療のための改良された方法
JP2694361B2 (ja) * 1989-02-09 1997-12-24 アストラ アクチエボラグ 抗菌剤

Also Published As

Publication number Publication date
CA2089748A1 (en) 1992-02-25
CA2089748C (en) 2005-07-05
EP0544760B1 (de) 1997-05-02
GB9018603D0 (en) 1990-10-10
WO1992003135A1 (en) 1992-03-05
EP0544760A1 (de) 1993-06-09
DK0544760T3 (da) 1997-09-22
CY2167B1 (en) 2002-08-23
AU8424091A (en) 1992-03-17
KR930701166A (ko) 1993-06-11
AU658831B2 (en) 1995-05-04
JPH06503806A (ja) 1994-04-28
GR3024058T3 (en) 1997-10-31
DE69125940T2 (de) 1997-12-18
DE69125940D1 (de) 1997-06-05
ES2103825T3 (es) 1997-10-01

Similar Documents

Publication Publication Date Title
DE69736441D1 (de) Pharmazeutische zusammensetzung zur behandlung von neurologischen und neuropsychiatrischen erkrankungen
ATE82121T1 (de) Arzneimittel fuer die therapeutische behandlung von alopezie.
ATE252901T1 (de) Arzneimittel zur behandlung von entzündlichen herzkrankheiten
ATE411026T1 (de) Mittel zur behandlung der alzheimer-krankheit
ATE114113T1 (de) Verwendung von droloxifen bei der behandlung von knochenerkrankungen.
ATE123943T1 (de) Mittel zur behandlung und vorbeugung von bauchentzündungen, die als wirkstoff zink-l- carnosin-salze oder -komplexe enthalten.
RU93032613A (ru) Фармацевтический препарат для лечения пациентов с пролонгированным временем коагуляции, способ лечения пациентов, применение epi ингибитора для получения фармацевтического препарата
NO902800D0 (no) Fremgangsmaate for fremstilling av 11beta-aryl-4-oestrener.
NO972391D0 (no) 2-substituerte 1,2,5-tiadiazolidin-3-on 1,1-dioksider og preparater og metoder for anvendelse derav
ATE152350T1 (de) Pharmazeutische zusammensetzungen die 5- difluormethoxy-2-(3,4-dimethoxy-2- pyridyl)methylsulfinyl>-1h-benzimidazol und ein anti-heliobactermittel enthalten zur behandlung von magen-darm krankheiten
DE68929388D1 (de) Aus Harn isolierte antikoagulierende Verbindung
ATE124681T1 (de) Arzneimittelzusammensetzungen zur behandlung von psoriasis.
DK0443848T3 (da) Nyt antiulcermiddel
DE68903059D1 (de) Strontiumsalz, verfahren zu dessen herstellung und arzneimittel, die es enthalten.
ATE5256T1 (de) Phenylpiperazinderivate von 1,3,4oxadiazolylphenolen, ihre herstellung und diese enthaltende therapeutische mittel.
DE68905076D1 (de) Pharmazeutische zusammensetzung fuer die behandlung von hautwunden.
DE68916651D1 (de) Heilmittel zur behandlung von toxoplasmose.
FI925546A7 (fi) Amidiliittyneitä pyridyylihappojohdannaisia leukotrieeniin liittyvien sairauksien hoitamiseksi
ID20165A (id) Penggunaan asam 2-(3,4-dimetoksisinamoil)aminobenzoat untuk pembuatan obat untuk pengobatan atau pencegahan restenosis
ATE106883T1 (de) Azelastin-embonat, verfahren zu seiner herstellung und pharmazeutische zubereitungen, die als wirkstoff azelastin-embonat enthalten.
ATE67931T1 (de) Butylhydroxyanisole zur behandlung von retrovirus-krankheiten.
ATE69809T1 (de) Leukotrienantagonisten, verfahren zu ihrer herstellung, ihre anwendung zur behandlung von krankheiten.
DK417889A (da) Anvendelse af 2-azabicyklo(2.2.2.)-carboxylsyrederivater til fremstilling af medicinske produkter til behandling af vaskulaere sygdomme
DE69104058D1 (de) N-[(2-thenoylmerkapto-3-methyl)-butanoyl]-homocysteinthiolacton, verfahren zu seiner herstellung und diese enthaltende pharmaceutische zusammensetzungen.
DE68914886D1 (de) Mittel zur Behandlung von Raynaud's Krankheit.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
EEFA Change of the company name
EELA Cancelled due to lapse of time